{"id":44203,"date":"2022-05-23T11:01:35","date_gmt":"2022-05-23T09:01:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/"},"modified":"2022-05-23T11:01:35","modified_gmt":"2022-05-23T09:01:35","slug":"modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/","title":{"rendered":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer"},"content":{"rendered":"
\n

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals<\/a> (\u201cModra\u201d) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006\/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 \u2013 7, 2022 virtually and in-person in Chicago, IL, USA.\n<\/p>\n

<\/a><\/p>\n

\nPlease see below for details on the poster abstract.\n<\/p>\n

\nSession: <\/b>Genitourinary Cancer\u2014Prostate, Testicular, and Penile\n<\/p>\n

\nPoster Title: <\/b>A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006\/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).\n<\/p>\n

\nPresenter: <\/b>Ulka N. Vaishampayan, MD | University of Michigan\n<\/p>\n

\nLocation: <\/b>In-Person & Live Stream | Arie Crown Theater\n<\/p>\n

\nSession Date and Time: <\/b>June 6, 2022 from 16:30 CDT \u2013 18:00 CDT\n<\/p>\n

\nAbstract Number: <\/b>5016\n<\/p>\n

\nPoster Number: <\/b>200\n<\/p>\n

\nAbout metastatic Castration-Resistant Prostate Cancer (mCRPC)<\/b>\n<\/p>\n

\nmCRPC is an advanced form of prostate cancer and the fourth most common cause of cancer death overall. mCRPC is not amenable to surgical treatment and resistant to androgen deprivation therapy, a hormone therapy used as initial disease management to reduce growth of prostate cancer cells.\n<\/p>\n

\nAbout ModraDoc006\/r<\/b>\n<\/p>\n

\nModraDoc006\/r is a proprietary boosted taxane therapy based on docetaxel, an intravenously administered therapy, that is very broadly used in a variety of tumor types. ModraDoc006 \u2013 an oral docetaxel tablet – is given in combination with ritonavir (r), which acts as a booster to increase the systemic bioavailability of ModraDoc006. ModraDoc006\/r is designed to combine the convenience and practicality of taking chemotherapy treatment at home with the potential for an improved safety profile, as compared to standard IV docetaxel.\n<\/p>\n

\nAbout Modra Pharmaceuticals<\/b>\n<\/p>\n

\nModra Pharmaceuticals aims to transform taxane therapy by developing therapies that are less toxic, more effective and can be taken at home in tablet form. The Company\u2019s goal is to dramatically improve the therapeutic outcomes and everyday lives of the hundreds of thousands of cancer patients undergoing taxane therapy worldwide. Modra\u2019s lead program completed a Phase 2b clinical study in prostate cancer, resulting in positive date further supporting the delivery, bioavailability and tolerability of its novel approach.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nColin Freund
\n
CEO, Modra Pharmaceuticals
\n
colin.freund@modrapharmaceuticals.com<\/a>
Tel: +1 609 933 8008\n<\/p>\n

\nTrophic Communications
\n
Valeria Fisher or Desmond James
\n
modra@trophic.eu<\/a>
Tel: +49 (0) 175 804 1816 or +49 (0) 1516 7859086\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (\u201cModra\u201d) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006\/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 \u2013 7, 2022 virtually and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44203","6":"format-standard","7":"category-industry"},"yoast_head":"\nModra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (\u201cModra\u201d) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006\/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 \u2013 7, 2022 virtually and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-23T09:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\\\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer\",\"datePublished\":\"2022-05-23T09:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/\"},\"wordCount\":392,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220523005080\\\/en\\\/1080272\\\/21\\\/modra_logo_new.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/\",\"name\":\"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\\\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220523005080\\\/en\\\/1080272\\\/21\\\/modra_logo_new.jpg\",\"datePublished\":\"2022-05-23T09:01:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220523005080\\\/en\\\/1080272\\\/21\\\/modra_logo_new.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220523005080\\\/en\\\/1080272\\\/21\\\/modra_logo_new.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\\\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend","og_description":"AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (\u201cModra\u201d) today announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006\/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) at the upcoming ASCO General Annual Meeting held from June 3 \u2013 7, 2022 virtually and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-23T09:01:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer","datePublished":"2022-05-23T09:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/"},"wordCount":392,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/","url":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/","name":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg","datePublished":"2022-05-23T09:01:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220523005080\/en\/1080272\/21\/modra_logo_new.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/modra-pharmaceuticals-to-present-new-phase-2b-data-at-the-2022-asco-general-annual-meeting-on-modradoc006-r-a-boosted-oral-taxane-for-patients-with-metastatic-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006\/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44203"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44203\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}